Global Colorectal Cancer Screening and Diagnostics Market

Report Highlights

The global market for colorectal cancer screening and diagnostic testing services is estimated to increase from $40.0 billion in 2024 to reach $46.1 billion by 2029, at a compound annual growth rate (CAGR) of 2.9% from 2024 through 2029.

Report Includes

• 37 data tables and 71 additional tables
• Analyses of trends in the global market for colorectal cancer screening and diagnostics, with sales data for 2021-2023, estimates for 2024, and projections of compound annual growth rates (CAGRs) through 2029
• Estimates and forecasts of the market size by type, end user and geographic region
• Discussion of emerging technologies and developments, and the macroeconomic factors affecting the market
• Coverage of stages, etiology, pathophysiology, and risk factors of colorectal cancer, and discussion on its diagnosis, regulatory framework and reimbursement scenarios
• Information on product pipeline, approvals, launches and expansions and funding and grants in the medical industry
• Review of patent data and other new developments
• Discussion of ESG challenges and practices of the industry
• Assessment of the competitive landscape, including the market shares of leading companies, their product portfolios and financial overviews
• Information on recent mergers and acquisitions, expansions, collaborations, investments, and divestments
• Company profiles of major players within the industry, including Fujifilm Holdings Corp., Olympus Corp., Exact Sciences Corp., Danaher Corp., and Guardant Health

Report Scope

This report summarizes the colorectal cancer screening and diagnostic testing service market, including a market snapshot and company profiles of leading product manufacturers/service providers. It provides a comprehensive market breakdown with in-depth information regarding each segment. The overview section of the report describes market trends and dynamics, including drivers, challenges, and opportunities. It provides information on emerging technologies and developments in the industry. The report also analyzes critical market players’ financials, product portfolios, and recent activities.

BCC Research analyzed and made projections of each market and its applications, along with forecasts for the next five years. The report also features profiles of leading product manufacturers/service providers in the colorectal cancer screening and diagnostic testing service industry, including Fujifilm Holdings Corporation, Olympus Corporation, Exact Sciences Corporation, Danaher Corporation, Guardant Health, New Horizon Health, and Quest Diagnostics.

The market is segmented by geographical region into North America, Europe, Asia-Pacific, and the Rest of the World (RoW). Regional analysis is further segregated:

• North America: The U.S., Canada, and Mexico.
• Europe: Germany, the U.K., France, Italy, Spain, and the Rest of Europe.
• Asia-Pacific: China, Japan, India, South Korea, Australia, and the Rest of Asia-Pacific.

Data for market estimates have been provided for 2021 and 2022 as the historical years and 2023 as the base year, with the forecast through 2029.

Analyst Credentials

BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.

Consulting Editor’s Credentials

Dr. Marianna Tcherpakov has more than 10 years of experience as a bench scientist specializing in the areas of biochemistry, cell biology, assay development, antibody and drug manufacturing. She has authored several scientific publications in peer review journals. In the last 10 years, Marianna worked as a business development professional in CRO/CDMO industry. She is familiar with pharmaceutical and biotech landscape, trends and potential future developments in industry.